Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pars Rus is a pharmaceutical company based in Moscow, Russia, that serves as the official representative and strategic distributor for the Tamin Pharmaceutical Investment Company (TPICO), Iran's largest pharmaceutical holding. The company specializes in the registration, marketing, and distribution of a broad range of Iranian-manufactured medicinal products, including oncology drugs, hormones, and complex injectables, within the Russian and CIS markets. By facilitating the entry of high-quality generics and biosimilars from TPICO's subsidiaries—such as Aburaihan Pharmaceutical and Caspian Tamin—Pars Rus provides essential and cost-effective therapeutic options to the Russian healthcare system. The company plays a pivotal role in strengthening bilateral pharmaceutical trade and ensuring supply chain resilience between Russia and Iran. Pars Rus is actively involved in navigating regulatory requirements and managing logistics to maintain a consistent supply of critical medications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pars Rus.